1h Free Analyst Time
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules. It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2.Speak directly to the analyst to clarify any post sales queries you may have.
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 25 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 8 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 4 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Genetic Disorders, Musculoskeletal Disorders, Ear Nose Throat Disorders, Ophthalmology and Undisclosed which include indications Alzheimer's Disease, Lung Cancer, Pancreatic Cancer, Breast Cancer, Dementia Associated With Alzheimer's Disease, Ovarian Cancer, Tauopathies, Acute Sensorineural Hearing Loss, Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Angiosarcoma, Bipolar Disorder (Manic Depression), Bone Disorders, Bone Fracture, Bone Sarcoma, Central Nervous System (CNS) Tumor, Cognitive Impairment, Ependymoma, Esophageal Cancer, Ewing Sarcoma, Frontotemporal Dementia (FTD), Glioblastoma Multiforme (GBM), Hearing Disorders, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liposarcoma, Liver Cancer, Lymphoma, Major Depressive Disorder, Menkes Disease (Kinky Hair Disease), Metastatic Lung Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Multiple Sclerosis, Myelofibrosis, Myotonic Dystrophy, Neuroblastoma, Neurodegenerative Diseases, Osteogenesis Imperfecta, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Post-Traumatic Stress Disorder (PTSD), Prostate Cancer, Retinitis Pigmentosa (Retinitis), Rhabdomyosarcoma, Salivary Gland Cancer, Sarcomas, Soft Tissue Sarcoma, Solid Tumor, Synovial Sarcoma, T-Cell Leukemia, Tay-Sachs Disease, Unspecified and Unspecified Central Nervous System Disorders.
The latest report Glycogen Synthase Kinase 3 Beta - Drugs In Development, 2022, outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
- The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Overview
- Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
- Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles
- Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Products
- Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products
- Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Product Development Milestones
- Featured News & Press Releases
- Sep 21, 2022: IGC announces issuance of second patent for the treatment of Alzheimer’s Using THC
- Sep 16, 2022: Quince Therapeutics presents preclinical data at MHSRS 2022 demonstrating preclinical efficacy of bone-targeting platform for traumatic bone injury
- Sep 12, 2022: Quince Therapeutics presents preclinical data at ASBMR 2022 demonstrating application of bone-targeting platform for spinal fusion and bone cancer indications
- Aug 30, 2022: Quince Therapeutics presents preclinical data at OI 2022 demonstrating potential of a targeted anabolic for accelerated bone healing of osteogenesis imperfecta fractures
- Jul 18, 2022: Alzamend Neuro receives positive pre-IND response from FDA for AL001 treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder
- Jun 03, 2022: Innovative hearing restoration trial launches at the Medical College of Wisconsin
- May 17, 2022: Alzamend Neuro announces pre-IND submission for AL001 as a treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder
- May 05, 2022: Alzamend Neuro announces initiation of phase IIA multiple ascending dose clinical trial for AL001 treatment of dementia related to Alzheimer’s
- Apr 11, 2022: Alzamend Neuro contracts with Altasciences and iResearch Atlanta to manage and conduct its phase IIA study in patients with Alzheimer’s
- Mar 28, 2022: Actuate Therapeutics announces poster presentations at the 2022 AACR Annual Meeting
- Mar 28, 2022: Alzamend Neuro announces full data set from phase 1 first-in-human clinical trial for AL001 treatment of Dementia Related to Alzheimer’s
- Mar 11, 2022: ENTA conducting clinical trial of investigational regenerative medication to restore hearing function in sensorineural hearing loss (SNHL) patients
- Mar 01, 2022: Actuate Therapeutics announces first patient enrolled in Phase 2 clinical trial of elraglusib plus retifanlimab as investigational first line therapy for patients with advanced pancreatic cancer
- Feb 07, 2022: Actuate Therapeutics announces initiation of a multicenter randomized trial of elraglusib plus FOLFIRINOX as first line therapy for advanced pancreatic cancer
- Dec 22, 2021: AMO Pharma announces expansion of pivotal REACH-CDM study in congenital myotonic dystrophy
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Actuate Therapeutics Inc
- Alzamend Neuro Inc
- AMO Pharma Ltd
- Angelini Spa
- Ankar Pharma SL
- Avenzoar Pharmaceuticals Inc
- CerebraMed
- Collaborative Medicinal Development LLC
- Frequency Therapeutics Inc
- IGC Pharma LLC
- InnoBioscience LLC
- Mercaptor Discoveries Inc
- Novosteo Inc
- Park of Active Molecules
- Recursion Pharmaceuticals Inc
- Zovis Pharmaceuticals
